oncbrain — oncology meeting digest https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Sat, 08 Aug 2026 00:00:00 GMT BEACON-HCC https://oncbrain.oncologytoolkit.com/2026-08-08/#beacon-hcc https://oncbrain.oncologytoolkit.com/2026-08-08/#beacon-hcc Sat, 08 Aug 2026 00:00:00 GMT hepatobiliary [Consensus] New North American HCC allocation framework; expert decisions 96.6% concordant with BEACON vs 72.4% with BCLC 2025 across 29 cases. Eligible: HCC across all stages, North American practice context IROCK Contouring Guidelines (RCC SABR) https://oncbrain.oncologytoolkit.com/2026-07-31/#irock-rcc-sabr-contouring https://oncbrain.oncologytoolkit.com/2026-07-31/#irock-rcc-sabr-contouring Fri, 31 Jul 2026 00:00:00 GMT kidney [Consensus] First international consensus contouring atlas for RCC SABR: median DSC 0.85 across 16 experts, 4 scenario-specific iGTV statements. Eligible: Localized RCC considered for SABR, including IVC thrombus, post-RN or post-RFA recurrence EANO Consensus Statement on Radiation Necrosis https://oncbrain.oncologytoolkit.com/2026-07-13/#eano-radiation-necrosis-consensus https://oncbrain.oncologytoolkit.com/2026-07-13/#eano-radiation-necrosis-consensus Mon, 13 Jul 2026 00:00:00 GMT cns [Consensus] Delphi consensus: 53/57 statements reached ≥80% agreement across 20 experts; perfusion MRI + amino acid PET preferred, bevacizumab for steroid-refractory RN. Eligible: Post-cranial-RT pts with a new enhancing lesion, glioma or brain metastases ESTRO OCSCC Post-op CTV Delineation Guidelines https://oncbrain.oncologytoolkit.com/2026-07-08/#estro-ocscc-ctv-guidelines https://oncbrain.oncologytoolkit.com/2026-07-08/#estro-ocscc-ctv-guidelines Wed, 08 Jul 2026 00:00:00 GMT head-neck [Consensus] First ESTRO guideline for post-op CTV delineation in oral cavity SCC: GTV-P pre-op + 10 mm composited with surgical defect/flap + 5 mm. Eligible: Resected oral cavity SCC proceeding to post-operative radiotherapy American Radium Society AUC: Local Intraprostatic Recurrence https://oncbrain.oncologytoolkit.com/2026-07-08/#ars-auc-intraprostatic-recurrence https://oncbrain.oncologytoolkit.com/2026-07-08/#ars-auc-intraprostatic-recurrence Wed, 08 Jul 2026 00:00:00 GMT prostate [Consensus] Severe GU toxicity 20% after salvage RP vs 5.6% SBRT, 9.6% HDR: panel prefers biopsy-confirmed reirradiation. Eligible: Isolated intraprostatic recurrence after definitive prostate RT